Gasherbrum Bio, Inc.
Clinical trials sponsored by Gasherbrum Bio, Inc., explained in plain language.
Biotech subsidiary focused on developing therapies, owned by Structure Therapeutics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to help people with diabetes shed pounds and control blood sugar Results expected Sep 2026 (estimated) May already have reported ↗
-
New daily pill shows promise for weight loss in Mid-Stage trial
Disease control CompletedThis study tests an experimental daily pill called aleniglipron for weight loss in 220 adults with obesity or overweight who also have a weight-related health issue. Participants receive either the drug or a placebo for 36 weeks, with the option to continue on the drug for anothe…
Phase 2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill shows promise for shedding pounds in obesity trial
Disease control CompletedThis study tested a new drug called aleniglipron (GSBR-1290) to help people with obesity or overweight lose weight. About 85 adults took either the drug or a placebo for 44 weeks, along with diet and exercise. The main goal was to check safety and side effects, while also measuri…
Phase 2 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC